There are plenty of underappreciated stocks on the market. Look at Viking Therapeutics (NASDAQ:VKTX), for example. When I first highlighted VKTX on June 22, 2023, it traded at just $22 a share. At the time, it was nearing Phase 2 trials, with Phase 1 already showing the VK2735 triggered feelings of fullness in the body, which can help lead to weight loss. Still, even with that news, the stock was unappreciated. Today, though, as its story and the weight loss treatment boom have become far more popular, VKTX ...